GILEAD SCIENCES INC
For the period ended Dec 31, 2023. Filed Feb 23, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 23, 2024
GILD$170.87+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Income
| Year Ended December 31, | |||
|---|---|---|---|
| (in millions, except per share amounts) | 2023 | 2022 | 2021 |
| Revenues: | |||
| Product sales | $26,934 | $26,982 | $27,008 |
| Royalty, contract and other revenues | 182 | 299 | 297 |
| Total revenues | 27,116 | 27,281 | 27,305 |
| Costs and expenses: | |||
| Cost of goods sold | 6,498 | 5,657 | 6,601 |
| Research and development expenses | 5,718 | 4,977 | 4,601 |
| Acquired in-process research and development expenses | 1,155 | 944 | 939 |
| In-process research and development impairments | 50 | 2,700 | — |
| Selling, general and administrative expenses | 6,090 | 5,673 | 5,246 |
| Total costs and expenses | 19,511 | 19,951 | 17,387 |
| Operating income | 7,605 | 7,330 | 9,918 |
| Interest expense | (944) | (935) | (1,001) |
| Other income (expense), net | 198 | (581) | (639) |
| Income before income taxes | 6,859 | 5,814 | 8,278 |
| Income tax expense | (1,247) | (1,248) | (2,077) |
| Net income | 5,613 | 4,566 | 6,201 |
| Net loss attributable to noncontrolling interest | 52 | 26 | 24 |
| Net income attributable to Gilead | $5,665 | $4,592 | $6,225 |
| Basic earnings per share attributable to Gilead | $4.54 | $3.66 | $4.96 |
| Shares used in basic earnings per share attributable to Gilead calculation | 1,248 | 1,255 | 1,256 |
| Diluted earnings per share attributable to Gilead | $4.50 | $3.64 | $4.93 |
| Shares used in diluted earnings per share attributable to Gilead calculation | 1,258 | 1,262 | 1,262 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.